vs
Elastic N.V.（ESTC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Elastic N.V.的1.8倍（$772.1M vs $423.5M），Revvity净利率更高（12.7% vs -12.1%，领先24.9%），Elastic N.V.同比增速更快（15.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $26.0M），过去两年Elastic N.V.的营收复合增速更高（13.6% vs 9.0%）
Elastic是荷美合资软件企业，2012年成立于荷兰阿姆斯特丹，运营总部分设于荷兰及美国加利福尼亚州旧金山市，于纽交所上市。公司提供企业级搜索、可观测性、网络安全平台，可支持用户实现大规模数据搜索分析、系统性能监测及异常检测。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ESTC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$423.5M
营收增速更快
ESTC
高出10.1%
5.9%
净利率更高
RVTY
高出24.9%
-12.1%
自由现金流更多
RVTY
多$135.8M
$26.0M
两年增速更快
ESTC
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $423.5M | $772.1M |
| 净利润 | $-51.3M | $98.4M |
| 毛利率 | 75.9% | — |
| 营业利润率 | -1.9% | 14.5% |
| 净利率 | -12.1% | 12.7% |
| 营收同比 | 15.9% | 5.9% |
| 净利润同比 | -101.5% | 3.9% |
| 每股收益（稀释后） | $-0.48 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESTCRVTY
| Q4 25 | $423.5M | $772.1M | ||
| Q3 25 | $415.3M | $698.9M | ||
| Q2 25 | $388.4M | $720.3M | ||
| Q1 25 | $382.1M | $664.8M | ||
| Q4 24 | $365.4M | $729.4M | ||
| Q3 24 | $347.4M | $684.0M | ||
| Q2 24 | $335.0M | $691.7M | ||
| Q1 24 | $328.0M | $649.9M |
净利润ESTCRVTY
| Q4 25 | $-51.3M | $98.4M | ||
| Q3 25 | $-24.6M | $46.7M | ||
| Q2 25 | $-16.4M | $53.9M | ||
| Q1 25 | $-17.1M | $42.2M | ||
| Q4 24 | $-25.4M | $94.6M | ||
| Q3 24 | $-49.2M | $94.4M | ||
| Q2 24 | $-41.1M | $55.4M | ||
| Q1 24 | $176.1M | $26.0M |
毛利率ESTCRVTY
| Q4 25 | 75.9% | — | ||
| Q3 25 | 76.7% | 53.6% | ||
| Q2 25 | 74.8% | 54.5% | ||
| Q1 25 | 74.6% | 56.5% | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 73.6% | 56.3% | ||
| Q2 24 | 73.8% | 55.7% | ||
| Q1 24 | 74.2% | 54.6% |
营业利润率ESTCRVTY
| Q4 25 | -1.9% | 14.5% | ||
| Q3 25 | -2.3% | 11.7% | ||
| Q2 25 | -3.1% | 12.6% | ||
| Q1 25 | -1.2% | 10.9% | ||
| Q4 24 | -1.2% | 16.3% | ||
| Q3 24 | -9.7% | 14.3% | ||
| Q2 24 | -13.6% | 12.4% | ||
| Q1 24 | -8.1% | 6.8% |
净利率ESTCRVTY
| Q4 25 | -12.1% | 12.7% | ||
| Q3 25 | -5.9% | 6.7% | ||
| Q2 25 | -4.2% | 7.5% | ||
| Q1 25 | -4.5% | 6.4% | ||
| Q4 24 | -7.0% | 13.0% | ||
| Q3 24 | -14.2% | 13.8% | ||
| Q2 24 | -12.3% | 8.0% | ||
| Q1 24 | 53.7% | 4.0% |
每股收益（稀释后）ESTCRVTY
| Q4 25 | $-0.48 | $0.86 | ||
| Q3 25 | $-0.23 | $0.40 | ||
| Q2 25 | $-0.15 | $0.46 | ||
| Q1 25 | $-0.16 | $0.35 | ||
| Q4 24 | $-0.25 | $0.77 | ||
| Q3 24 | $-0.48 | $0.77 | ||
| Q2 24 | $-0.35 | $0.45 | ||
| Q1 24 | $1.69 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | $570.3M | — |
| 股东权益账面价值 | $891.1M | $7.3B |
| 总资产 | $2.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.64× | — |
8季度趋势，按日历期对齐
现金及短期投资ESTCRVTY
| Q4 25 | $1.4B | $919.9M | ||
| Q3 25 | $1.5B | $931.4M | ||
| Q2 25 | $1.4B | $991.8M | ||
| Q1 25 | $584.0M | $1.1B | ||
| Q4 24 | $658.5M | $1.2B | ||
| Q3 24 | $594.9M | $1.2B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $526.9M | $1.7B |
总债务ESTCRVTY
| Q4 25 | $570.3M | — | ||
| Q3 25 | $570.0M | — | ||
| Q2 25 | $569.7M | — | ||
| Q1 25 | $569.4M | — | ||
| Q4 24 | $569.2M | — | ||
| Q3 24 | $568.9M | — | ||
| Q2 24 | $568.6M | — | ||
| Q1 24 | $568.3M | — |
股东权益ESTCRVTY
| Q4 25 | $891.1M | $7.3B | ||
| Q3 25 | $971.4M | $7.4B | ||
| Q2 25 | $927.2M | $7.6B | ||
| Q1 25 | $859.1M | $7.6B | ||
| Q4 24 | $811.5M | $7.7B | ||
| Q3 24 | $759.4M | $7.9B | ||
| Q2 24 | $738.2M | $7.9B | ||
| Q1 24 | $707.8M | $7.8B |
总资产ESTCRVTY
| Q4 25 | $2.5B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.2B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比ESTCRVTY
| Q4 25 | 0.64× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 0.80× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $26.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.1% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $302.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ESTCRVTY
| Q4 25 | $26.6M | $182.0M | ||
| Q3 25 | $104.8M | $138.5M | ||
| Q2 25 | $87.0M | $134.3M | ||
| Q1 25 | $88.1M | $128.2M | ||
| Q4 24 | $38.4M | $174.2M | ||
| Q3 24 | $52.8M | $147.9M | ||
| Q2 24 | $60.9M | $158.6M | ||
| Q1 24 | $52.4M | $147.6M |
自由现金流ESTCRVTY
| Q4 25 | $26.0M | $161.8M | ||
| Q3 25 | $104.2M | $120.0M | ||
| Q2 25 | $84.9M | $115.5M | ||
| Q1 25 | $87.3M | $112.2M | ||
| Q4 24 | $37.7M | $149.8M | ||
| Q3 24 | $52.0M | $125.6M | ||
| Q2 24 | $60.1M | $136.6M | ||
| Q1 24 | $51.3M | $129.7M |
自由现金流率ESTCRVTY
| Q4 25 | 6.1% | 21.0% | ||
| Q3 25 | 25.1% | 17.2% | ||
| Q2 25 | 21.8% | 16.0% | ||
| Q1 25 | 22.8% | 16.9% | ||
| Q4 24 | 10.3% | 20.5% | ||
| Q3 24 | 15.0% | 18.4% | ||
| Q2 24 | 17.9% | 19.7% | ||
| Q1 24 | 15.6% | 20.0% |
资本支出强度ESTCRVTY
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
现金转化率ESTCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.30× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESTC
| Self Managed Subscription | $192.0M | 45% |
| Saa S Self Managed Annual | $156.9M | 37% |
| Saa S Self Managed Monthly | $48.8M | 12% |
| Professional Services | $25.8M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
